{"Clinical Trial ID": "NCT00900627", "Intervention": ["INTERVENTION 1:", "AZD8931 160 mg bd", "Part A: AZD8931 160mg (bd) plus paclitaxel weekly of 90mg/m2 on days 1, 8 and 15 of each 28-day cycle", "INTERVENTION 2:", "AZD8931 120 mg bd", "Part A: AZD8931 120mg (bd) plus paclitaxel weekly of 90mg/m2 on days 1, 8 and 15 of each 28-day cycle"], "Eligibility": ["Incorporation criteria:", "Men/ women with a solid malignant tumour that does not respond to standard treatments (Phase I). Patients with advanced low-term breast cancer HER2 (Phase II)", "Suitable for paclitaxel chemotherapy", "\u2022 Life expectancy greater than 12 weeks", "- Exclusion criteria:", "Renal, hepatic, cardiac, gastric, pulmonary or eye impairment", "Hypersensitive to paclitaxel", "No symptomatic uncontrolled brain metastases", "Previous taxane chemotherapy within 12 months (phase II)"], "Results": ["Performance measures:", "Phase I: Number of dose-limiting toxicities in AZD8931 in combination with weekly paclitaxel", "DLT is a laboratory abnormality related to AZD8931, starting from the DLT assessment period and meeting one of the following criteria (more details in the protocol): surface symptomatic eye injury; CTCAE Grade 4 haematological EE; CTCAE Grade 3 haematological EE of febrile neutropenia / neutropenia / thrombocytopenia / hyperkalaemia / hyperglycaemia / hypotension / urological toxicity / ILD / pneumonitis; QTcF interval > 500 msec, two ECGs at 30 minutes interval; symptomatic congestive heart failure and decreased FEVL; Decreased FEVL by 20% below the NSA; CTCAE Grade 3 skin rash remaining for 5 days despite optimal treatment; Grade 3 nausea, vomiting or diarrhoea of CTCAE, despite optimal treatment; Other Grade 3 toxicity of CTCAE, which, from the 7-day cycle opinion of the 2D-investigator, are CS and are related to AZD.", "Timeline: Weekly routine safety monitoring visits from day 1 to day 28 for each participant", "Results 1:", "Title of arm/group: AZD8931 160 mg bd", "Part A: AZD8931 160mg (bd) plus paclitaxel weekly of 90mg/m2 on days 1, 8 and 15 of each 28-day cycle", "Total number of participants analysed: 6", "Type of measurement: Number", "Unit of measure: Number of dose limit toxicities Total: 2", "Eye disorders: Keratitis: 1", "Eye disorders: Photophobia: 1", "Gastrointestinal disorders: Diarrhoea: 1", "Gastrointestinal disorders: oesophagitis: 0", "Infections and infestations: Pustular Rash: 0", "Results 2:", "Title of arm/group: AZD8931 120 mg bd", "Part A: AZD8931 120mg (bd) plus paclitaxel weekly of 90mg/m2 on days 1, 8 and 15 of each 28-day cycle", "Total number of participants analysed: 2", "Type of measurement: Number", "Unit of measure: Number of dose limit toxicities Total: 1", "Eye disorders: Keratitis: 0", "Eye disorders: Photophobia: 0", "Gastrointestinal disorders: Diarrhoea: 1", "Gastrointestinal disorders: oesophagitis: 0", "Infections and infestations: Pustular Rash: 0"], "Adverse Events": ["Undesirable Events 1:", "Total: 4/6 (66.67 per cent)", "ANEMIA 0/6 (0.00 %)", "NEUTROPENIA FEBRILE 0/6 (0.00 %)", "NEUTROPENIA 0/6 (0.00 %)", "PANCYTOPENIA 0/6 (0.00 %)", "- CARDIAC FAILURE 0/6 (0.00 %)", "ATMOSPHERIC FIBRILLATION 0/6 (0.00 %)", "Myocardial INFARCTION 0/6 (0.00 %)", "SUPRAVENTRICULAR TACHYCARDIA 0/6 (0.00 %)", "KERATITIS 0/6 (0.00 %)", "DIARRHOEA 0/6 (0.00 %)", "NAUSEA 0/6 (0.00 %)", "OESOPHAGITIS 0/6 (0.00 %)", "Adverse Events 2:", "Total: 2/6 (33.33 per cent)", "ANEMIA 0/6 (0.00 %)", "NEUTROPENIA FEBRILE 0/6 (0.00 %)", "NEUTROPENIA 0/6 (0.00 %)", "PANCYTOPENIA 0/6 (0.00 %)", "- CARDIAC FAILURE 0/6 (0.00 %)", "ATMOSPHERIC FIBRILLATION 0/6 (0.00 %)", "Myocardial INFARCTION 0/6 (0.00 %)", "SUPRAVENTRICULAR TACHYCARDIA 0/6 (0.00 %)", "KERATITIS 0/6 (0.00 %)", "DIARRHOEA 0/6 (0.00 %)", "NAUSEA 0/6 (0.00 %)", "OESOPHAGITIS 1/6 (16.67%)"]}